Holen Sie sich die Stockscreener-App
12.00
3.36%
0.39
Handel nachbörslich:
12.00
Schlusskurs vom Vortag:
$11.61
Offen:
$11.72
24-Stunden-Volumen:
646.48K
Relative Volume:
0.88
Marktkapitalisierung:
$880.06M
Einnahmen:
$125.58M
Nettoeinkommen (Verlust:
$-92.14M
KGV:
-9.6587
EPS:
-1.2424
Netto-Cashflow:
$-138.27M
1W Leistung:
+6.01%
1M Leistung:
+3.54%
6M Leistung:
+39.53%
1J Leistung:
-6.76%
1-Tages-Spanne:
$11.45
$12.08
1-Wochen-Bereich:
$11.22
$12.36
52-Wochen-Spanne:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.00 | 851.46M | 125.58M | -92.14M | -138.27M | -1.2424 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - TipRanks
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor, Genentech to End Protein Therapeutics Collaboration - TipRanks
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Retail Trends: Is Xencor Inc impacted by rising rates2025 Historical Comparison & Consistent Profit Trading Strategies - baoquankhu1.vn
Resistance Check: What is the long term forecast for Xencor Inc stock2025 Key Highlights & Community Consensus Picks - baoquankhu1.vn
Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc. - MarketBeat
Dahiyat, Xencor CEO, sells $80k in XNCR stock By Investing.com - Investing.com Australia
3,244-share sale planned by XNCR (NASDAQ: XNCR) — insider notice - Stock Titan
Insider sale and restricted vesting reported by Company (NASDAQ: XNCR) - Stock Titan
Xencor SVP Eckert sells $17,747 in shares By Investing.com - Investing.com Australia
Xencor faces royalty dispute with Alexion over Ultomiris sales By Investing.com - Investing.com Australia
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling - MarketBeat
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor - Bitget
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor sr. VP Desjarlais sells $31,676 in stock By Investing.com - Investing.com South Africa
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com Nigeria
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind - TipRanks
Xencor Updates Outlook Amid Ultomiris Royalty Dispute - TipRanks
Xencor says Alexion disputes U.S. Ultomiris royalties; updates cash guidance to $380–400M - TradingView
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire
XNCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(XNCR.O) | Stock Price & Latest News - Reuters
[144] Xencor Inc SEC Filing - Stock Titan
John Desjarlais plans to sell 2,663 XNCR shares (XNCR) — Form 144 notice - Stock Titan
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune - Investing.com Nigeria
Update Recap: Should value investors consider Xencor IncEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
Xencor, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
XNCR PE Ratio & Valuation, Is XNCR Overvalued - Intellectia AI
Xencor (NASDAQ:XNCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Xencor, Inc. (XNCR) Investor Outlook: Unpacking the 113% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):